Alt image -https://content.stockstotrade.com/wp-content/uploads/2026/10/nuwellis-jumps-47-after-pediatric-aquadex-study-announcement.webp

Nuwellis Jumps 60% After Pediatric Aquadex Study

TIM BOHEN•UPDATED OCT. 27, 2026, 3:45 PM ET
Reviewed by Jeff Zananiriand Fact-checked by Ben Sturgill

Nuwellis rose 60% after publishing pediatric Aquadex results that could support a wider device label.

NUWE Candlestick Chart

Get Free Alerts

Why Nuwellis Stock Jumped 60% Today

Nuwellis Inc. (NASDAQ: NUWE) is up 60% at $4.96 this afternoon after announcing published pediatric results for its Aquadex kidney-support system. Shares traded as low as around $3.25 and reached $5.95 by late morning, then held most of the gain.

What Nuwellis Inc. Does

Nuwellis makes Aquadex, a system that filters excess fluid from blood to support kidney function. It is used for children with acute kidney injury, fluid overload, or kidney failure.

Nuwellis Aquadex Pediatric Study Results

A registry study tracks patients treated in real-world care instead of assigning treatments. The study covered 91 pediatric patients at seven hospitals; 87% survived their treatment course, and 86.5% of procedures finished without interruption. Those observed results do not show that Aquadex outperformed another treatment.

Nuwellis Aquadex Label Expansion

The FDA, the U.S. device regulator, sets a cleared label that lists a device’s approved patients and uses. The current label covers patients weighing 20 kg and above; Nuwellis plans to use the study to support a proposed expansion to 5 kg and above. The publication itself does not change the label.

Quick Financial Overview

Nuwellis had $3.9M in cash and cash equivalents, meaning cash the company can spend, as of June 30, 2026. That cash covers about four months at the reported spending rate. Nuwellis is a very small publicly traded company, with a market value of $18.1M.

Nuwellis Revenue and Earnings

Nuwellis reported $2.0M in revenue and a net loss of $4.8M for its latest reported quarter.

Nuwellis Float and Trading Volume

about 19 million shares traded. The public float, meaning shares available for trading, is about 3.6 million shares. Demand outran that supply, though the same shares can trade more than once.

Nuwellis Share Offering Risk

Recent financing records include paperwork preparing shares or other investments for possible future sale and documents adding details about a share offering, or sale of company shares. They do not show sale terms or establish a new sale today. Any share sale could dilute holders, meaning it would reduce each existing share’s slice of the company.

Get Free Alerts

Nuwellis Stock Is down 99% Over Six Months

NUWE remains down 99% from the $350 level six months ago, so today’s rebound sits inside a steep longer-term decline. Still, the last daily move this large was sixty-one sessions ago, with sessions meaning trading days.

Nuwellis Operating Cash Use

Nuwellis used $3.2M to run its business during the reported quarter. That cash outflow shows the cost of keeping operations going while the company seeks broader use of its device.

Get Free Alerts

Conclusion

The next step is Nuwellis’ effort to seek the wider label, but no submission or decision date is set. An FDA grant would allow Aquadex to serve smaller patients; without one, the current label remains in place. Nuwellis needs to raise more money to fund its next steps, so financing pressure remains alongside the regulatory work.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.


The Game is Rigged

But Our AI-driven analysis Has Leveled the Playing Field

Sign up for access to institutional grade tools and insights – and join 10,000+ traders